» Articles » PMID: 27599161

Stage 4S Neuroblastoma Tumors Show a Characteristic DNA Methylation Portrait

Overview
Journal Epigenetics
Specialty Genetics
Date 2016 Sep 7
PMID 27599161
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Stage 4S neuroblastoma (NB) is a special type of NB found in infants with metastases at diagnosis and is associated with an excellent outcome due to its remarkable capacity to undergo spontaneous regression. As genomics have not been able to explain this intriguing clinical presentation, we here aimed at profiling the DNA methylome of stage 4S NB to better understand this phenomenon. To this purpose, differential methylation analyses between International Neuroblastoma Staging System (INSS) stage 4S, stage 4 and stage 1/2 were performed, using methyl-CpG-binding domain (MBD) sequencing data of 14 stage 4S, 14 stage 4, and 13 stage 1/2 primary NB tumors (all MYCN non-amplified in order not to confound results). Stage 4S-specific hyper- and hypomethylated promoters were determined and further characterized for genomic localization and function by cytogenetic band enrichment, gene set enrichment, transcription factor target enrichment and differential RNA expression analyses. We show that specific chromosomal locations are enriched for stage 4S differentially methylated promoters and that stage 4S tumors show characteristic hypermethylation of specific subtelomeric promoters. Furthermore, genes involved in important oncogenic pathways, in neural crest development and differentiation, and in epigenetic processes are differentially methylated and expressed in stage 4S tumors. Based on these findings, we describe new biological mechanisms possibly contributing to the stage 4S-specific tumor biology and spontaneous regression. In conclusion, this study is the first to describe the highly characteristic stage 4S DNA methylome. These findings will open new avenues to further unravel the NB pathology in general and stage 4S disease specifically.

Citing Articles

Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.

Li S, Mi T, Jin L, Liu Y, Zhang Z, Wang J J Cancer Res Clin Oncol. 2024; 150(3):148.

PMID: 38512513 PMC: 10957705. DOI: 10.1007/s00432-024-05650-4.


Dilemmas in the Management of an Infant with Neuroblastoma Metastasized to the Muscles.

Van Heerden J, van den Akker M, Verlooy J, Van Roy N, Laureys G, Norga K Case Rep Oncol. 2023; 16(1):558-567.

PMID: 37900821 PMC: 10601722. DOI: 10.1159/000531433.


Analyses of Transcriptomics Cell Signalling for Pre-Screening Applications in the Integrated Approach for Testing and Assessment of Non-Genotoxic Carcinogens.

Oku Y, Madia F, Lau P, Paparella M, Mcgovern T, Luijten M Int J Mol Sci. 2022; 23(21).

PMID: 36361516 PMC: 9659232. DOI: 10.3390/ijms232112718.


Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program.

Jimenez C, Antonelli R, Nadal-Ribelles M, Devis-Jauregui L, Latorre P, Sole C Mol Cancer. 2022; 21(1):175.

PMID: 36057593 PMC: 9440539. DOI: 10.1186/s12943-022-01643-4.


5-Methylcytosine and 5-Hydroxymethylcytosine Signatures Underlying Pediatric Cancers.

Jhanwar S, Deogade A Epigenomes. 2021; 3(2).

PMID: 34968232 PMC: 8594703. DOI: 10.3390/epigenomes3020009.


References
1.
Mao Z, Nadal-Ginard B . Functional and physical interactions between mammalian achaete-scute homolog 1 and myocyte enhancer factor 2A. J Biol Chem. 1996; 271(24):14371-5. DOI: 10.1074/jbc.271.24.14371. View

2.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

3.
Wang J, Duncan D, Shi Z, Zhang B . WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013; 41(Web Server issue):W77-83. PMC: 3692109. DOI: 10.1093/nar/gkt439. View

4.
Xiao Y, Hsiao T, Suresh U, Chen H, Wu X, Wolf S . A novel significance score for gene selection and ranking. Bioinformatics. 2012; 30(6):801-7. PMC: 3957066. DOI: 10.1093/bioinformatics/btr671. View

5.
Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G . Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget. 2015; 7(2):1960-72. PMC: 4811509. DOI: 10.18632/oncotarget.6477. View